Therefore, long-acting GLP-1 receptor agonists offer a viable treatment option for people with type 2 diabetes and effectively align with the ADAs standard of care recommendations by addressing more than just blood glucose levels
Federal regulators explicitly prohibit dietary supplement companies from marketing their products with claims to diagnose, treat, or cure diseases
Among individuals with obesity, MASLD prevalence exceeds 75%, whereas type 2 diabetes is associated with MASLD in 55%-70% of cases
Local Reactions Implant or Injection Site Reactions: Pain, redness, bruising, swelling, or itching at the site where the implant or injection was placed
However my daughter always complains of 'pain' afterwards and yesterday she said she felt stinging, burning and a 'warm thigh' too